Synapse Biomedical’s TransAeris system technology could reduce the ventilator burden in Covid-19 patients by 26%. Credit: Synapse Biomedical, Inc.

Synapse Biomedical has received the US Food and Drug Administration’s (FDA) emergency use authorisation (EUA) for its TransAeris DPS system that assists in weaning Covid-19 patients off of ventilators in healthcare settings.

The rise in the number of patients requiring prolonged mechanical ventilation (PMV) has lead to increased demand on hospital and ICU resources amid the Covid-19 pandemic.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The PMV patients are at the risk of developing ventilator-induced diaphragm dysfunction (VIDD), which further extends their ventilation.

Synapse Biomedical’s TransAeris system resolves this issue by conditioning a patient’s diaphragm to reduce or avoid VIDD. The company noted that the technology could reduce the ventilator burden in Covid-19 patients by 26%, ensuring the availability of more ventilators during the current crisis.

The system recently received CE Mark approval and is currently under clinical investigation in the US.

Synapse Biomedical president and CEO Anthony Ignagni said: “More than 2,000 patients have been successfully treated worldwide with our diaphragm, pacing technologies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We welcome the FDA’s leadership in providing this emergency pathway to get our latest TransAeris device into the hands of clinicians so they can help as many Covid-19 patients as possible during this pandemic.”

TransAeris was initially developed to assist patients with prolonged mechanical ventilation on a temporary basis up to 30 days, simplifying the external features of the company’s NeuRx DPS system.

The NeuRx DPS system is FDA and CE Mark approved for people with Spinal Cord Injury (SCI) since 2008. It is claimed to have successfully reduced or eliminated the need for mechanical ventilation in such patients.